Emerging Markets Earnings Roundup: Abbott Laboratories (Part 2)
This article was originally published in PharmAsia News
Abbott Laboratories now sees 40% of sales from emerging markets and has said a corner has been turned on its dairy nutrition business in China.
You may also be interested in...
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.